DK2717908T3 - CETP-fragmenter - Google Patents
CETP-fragmenter Download PDFInfo
- Publication number
- DK2717908T3 DK2717908T3 DK12729449.4T DK12729449T DK2717908T3 DK 2717908 T3 DK2717908 T3 DK 2717908T3 DK 12729449 T DK12729449 T DK 12729449T DK 2717908 T3 DK2717908 T3 DK 2717908T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- seq
- leu
- cetp
- peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Peptid, som består af 6 til 20 aminosyrerester og er afledt af aminosyresekvensen VFKGTLKYGYTTAWWLGIDQSIDFEIDSAI (SEQ ID No. 23), hvor peptidet omfatter aminosyresekvensen WWLGID (SEQ ID No. 24).
2. Peptid ifølge krav 1, kendetegnet ved at aminosyresekvensen af peptidet er valgt fra gruppen bestående af YTTAWWLGIDQS (SEQ ID No. 1), YGYTTAWWLGIDQSID (SEQ ID No. 7), TTAWWLGIDQS (SEQ ID No. 8), TAWWLGIDQS (SEQ ID No. 9), AWWLGIDQS (SEQ ID No. 10), WWLGIDQS (SEQ ID No. 11), YTTAWWLGIDQ (SEQ ID No. 13), YTTAWWLGID (SEQ ID No. 14), TTAWWLGIDQ (SEQ ID No. 18) og TTAWWLGID (SEQ ID No. 19).
3. Peptid ifølge krav 1 eller 2, kendetegnet ved at peptidet omfatter en cysteinrest ved dens C- og/eller N-terminal.
4. Peptid ifølge et hvilket som helst af kravene 1 til 3 til anvendelse til forebyggelse og/eller behanding af atherosclerose og sygdomme forbundet med atherosclerose.
5. Peptid ifølge krav 4, kendetegnet ved at sygdommen forbundet med atherosclerose er valgt fra gruppen bestående af perifer arteriel okklusiv sygdom, koronar hjertesygdom, apoplektisk cerebral insultus og slagtilfælde.
6. Peptid ifølge krav 4 eller 5, kendetegnet ved at peptidet administreres til et individ i en mængde på 0,5 til 500 pg, fortrinsvis 1 til 100 pg, pr. immunisering.
7. Vaccine omfattende mindst et peptid ifølge et hvilket som helst af kravene 1 til 3.
8. Vaccine ifølge krav 7, kendetegnet ved at mindst ét peptid er koblet eller bundet til en farmaceutisk acceptabel bærer, fortrinsvis KLH (Keyhole Limpet Hemocyanin).
9. Vaccine ifølge krav 7 eller 8, kendetegnet ved at mindst ét peptid er formuleret til intradermal, subkutan eller intramuskulær administration.
10. Vaccine ifølge et hvilket som helst af kravene 7 til 9, kendetegnet ved at mindst ét peptid er formuleret med en adjuvans, fortrinsvis aluminiumhydroxid.
11. Vaccine ifølge et hvilket som helst af kravene 7 til 10, kendetegnet ved at vaccinen omfatter det mindst ene peptid i en mængde på 0,5 til 500 pg, fortrinsvis 1 til 100 pg, pr. immunisering.
12. Vaccine ifølge et hvilket som helst af kravene 7 til 11 til anvendelse til forebyggelse og/eller behanding af atherosclerose og sygdomme forbundet med atherosclerose.
13. Vaccine ifølge krav 12, kendetegnet ved at sygdommen forbundet med atherosclerose er valgt fra gruppen bestående af perifer arteriel okklusiv sygdom, koronar hjertesygdom, apoplektisk cerebral insultus og slagtilfælde.
14. Antistof der binder til et peptid ifølge et hvilket som helst af kravene 1 til 3.
15. Antistof ifølge krav 14, kendetegnet ved at antistoffet omfatter en tung kædes variabel ("VH") region og en antistof-let kædes variabel ("VL") region, idet hver region omfatter komplementære bestemmende regioner, hvor de komplementært bestemmende regioner af VH-regionen har én eller flere af aminosyresekvenserne NVQLQESGPGLVKP-SQSLSLTCTVTGHSITSDYAWNWIRQFPGNKLEWMGYIT- NSGSTTYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCTRGGPYWGQGTLVTVSA (SEQ ID No. 104), EVQLVESGGGLVEPGGSLKLSCVASGFTFSTYAMSWFRLTPER-RLEWVAAISNGGSQNSYPDSVKGRFTVSRDNAK- NTLYLQMSSLRSEDTAMYYCSRNGNYFDYWGQGTTLTVSS (SEQ ID No. 105), DVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEW- MGYISYSGTTTYNPSLKSRISITRHTSKNQFFLQLNSVTTEDSATYYC-TRLGYYFDYWGQGTTLTVSS (SEQ ID No. 106) eller QIQLVQSGPELKKPGETVKISCKASGYTFTDCSMHWVKQAPGQGLK-WMGWINTKTGEPTYADDFKGRFAFSLETSASTAYLQINILKNEDSATY- FCAAHSGKDYAIDYWGQGTSVTVSS (SEQ ID No. 107), og VL-regionen har én eller flere af aminosyresekvenserne DIVMTQSQKFMSTSVG- DRVSITCKASQNVGTAWWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTITNMQSEDLA DYFCQQYSSYPLTFGAGTKLELK (SEQ ID No 108), QIVLTQSPAIMSASPGEKVTMTCSASSSISYMHWYQQKPGTSPKRWIFDTSKLASGVPARFSGSGSG TSYSLTISSMEAEDAATYYCHQRSSYPTFGSGTKLEIK (SEQ ID No. 109), DIVMTQSPASLAMSVGQKVTMNCKSSQSLLSSKNQKNFLAWYQQKPGQSPKVLVYFASTRASGVPD RFIGSGSGTDFTLTISSVQAEDLADYFCQQQYNTPLTFGAGTKLELK (SEQ ID No. 110) eller DVLMTQTPLSLPVSLGDQASISCRSSQSIVHRNGNTYLEW-YLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLRISRVEAQDLGVYFCFQGS-RVPPTFGGGTKLEIK (SEQ ID No. 111).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11169481A EP2532359A1 (en) | 2011-06-10 | 2011-06-10 | CETP fragments |
| PCT/EP2012/061038 WO2012168486A1 (en) | 2011-06-10 | 2012-06-11 | Cetp fragments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2717908T3 true DK2717908T3 (da) | 2015-08-03 |
Family
ID=44514130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12729449.4T DK2717908T3 (da) | 2011-06-10 | 2012-06-11 | CETP-fragmenter |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9085636B2 (da) |
| EP (2) | EP2532359A1 (da) |
| JP (1) | JP6336901B2 (da) |
| KR (1) | KR20140026390A (da) |
| CN (1) | CN103635204B (da) |
| AU (1) | AU2012266245B2 (da) |
| BR (1) | BR112013022164A2 (da) |
| CA (1) | CA2837767A1 (da) |
| DK (1) | DK2717908T3 (da) |
| ES (1) | ES2545458T3 (da) |
| IL (1) | IL227821A0 (da) |
| MX (1) | MX2013009521A (da) |
| RU (1) | RU2014100115A (da) |
| SG (1) | SG194425A1 (da) |
| WO (1) | WO2012168486A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR111760A1 (es) | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993011782A1 (en) | 1991-12-19 | 1993-06-24 | Southwest Foundation For Biomedical Research | Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments |
| WO1996015141A1 (en) | 1994-11-12 | 1996-05-23 | Lg Chemical Ltd. | Cholesteryl ester transfer protein inhibitor peptides and prophylactic and therapeutic anti-arteriosclerosis agents |
| US6410022B1 (en) | 1995-05-01 | 2002-06-25 | Avant Immunotherapeutics, Inc. | Modulation of cholesteryl ester transfer protein (CETP) activity |
| JP3580948B2 (ja) * | 1995-05-02 | 2004-10-27 | 日本たばこ産業株式会社 | ヒト由来ｃｅｔｐに反応性を有するモノクローナル抗体及びヒト由来ｃｅｔｐの定量方法 |
| WO2002098915A2 (en) * | 2001-06-07 | 2002-12-12 | Genfit | Compositions and methods for detecting or regulating cholesteryl ester transfer protein |
| AT500835B1 (de) | 2004-09-13 | 2007-12-15 | Affiris Forschungs & Entwicklungs Gmbh | Cholinestertransport-protein-mimotop als atherosklerose-medikament |
| US20060276400A1 (en) * | 2005-06-06 | 2006-12-07 | Hedy Adari | Modulation of cholesteryl ester transfer protein (CETP) activity |
| EP2137218A2 (en) | 2007-04-13 | 2009-12-30 | Novartis Ag | Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| AT505574B1 (de) | 2007-08-10 | 2009-09-15 | Affiris Forschungs & Entwicklungs Gmbh | Mimotope zur behandlung von atherosklerose |
| AT507604A1 (de) | 2008-11-19 | 2010-06-15 | Affiris Forschungs & Entwicklungs Gmbh | Behandlung von atherosklerose |
| ES2670576T3 (es) | 2009-09-03 | 2018-05-31 | Pfizer Vaccines Llc | Vacuna de PCSK9 |
-
2011
- 2011-06-10 EP EP11169481A patent/EP2532359A1/en not_active Withdrawn
-
2012
- 2012-06-11 ES ES12729449.4T patent/ES2545458T3/es active Active
- 2012-06-11 BR BR112013022164A patent/BR112013022164A2/pt not_active IP Right Cessation
- 2012-06-11 US US14/116,075 patent/US9085636B2/en not_active Expired - Fee Related
- 2012-06-11 CN CN201280028674.1A patent/CN103635204B/zh not_active Expired - Fee Related
- 2012-06-11 MX MX2013009521A patent/MX2013009521A/es not_active Application Discontinuation
- 2012-06-11 JP JP2014514110A patent/JP6336901B2/ja not_active Expired - Fee Related
- 2012-06-11 CA CA2837767A patent/CA2837767A1/en not_active Abandoned
- 2012-06-11 DK DK12729449.4T patent/DK2717908T3/da active
- 2012-06-11 EP EP12729449.4A patent/EP2717908B1/en not_active Not-in-force
- 2012-06-11 AU AU2012266245A patent/AU2012266245B2/en not_active Ceased
- 2012-06-11 SG SG2013061940A patent/SG194425A1/en unknown
- 2012-06-11 WO PCT/EP2012/061038 patent/WO2012168486A1/en active Application Filing
- 2012-06-11 RU RU2014100115/10A patent/RU2014100115A/ru not_active Application Discontinuation
- 2012-06-11 KR KR1020137025945A patent/KR20140026390A/ko not_active Application Discontinuation
-
2013
- 2013-08-06 IL IL227821A patent/IL227821A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2837767A1 (en) | 2012-12-13 |
| ES2545458T3 (es) | 2015-09-11 |
| EP2532359A1 (en) | 2012-12-12 |
| KR20140026390A (ko) | 2014-03-05 |
| EP2717908A1 (en) | 2014-04-16 |
| JP2014519512A (ja) | 2014-08-14 |
| BR112013022164A2 (pt) | 2018-06-26 |
| SG194425A1 (en) | 2013-12-30 |
| MX2013009521A (es) | 2013-10-01 |
| CN103635204B (zh) | 2016-03-30 |
| EP2717908B1 (en) | 2015-07-22 |
| RU2014100115A (ru) | 2015-07-20 |
| NZ613913A (en) | 2015-07-31 |
| CN103635204A (zh) | 2014-03-12 |
| US9085636B2 (en) | 2015-07-21 |
| WO2012168486A1 (en) | 2012-12-13 |
| JP6336901B2 (ja) | 2018-06-06 |
| IL227821A0 (en) | 2013-09-30 |
| AU2012266245B2 (en) | 2017-02-02 |
| US20140147456A1 (en) | 2014-05-29 |
| AU2012266245A1 (en) | 2013-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2570135T3 (da) | PCSK9-Vaccine | |
| KR20160124901A (ko) | Pcsk9 백신 | |
| TWI442933B (zh) | 胜肽、醫藥化合物及該醫藥化合物之使用 | |
| DK2890785T3 (da) | Pcsk9-peptidvaccine | |
| DK2717908T3 (da) | CETP-fragmenter | |
| NZ613913B2 (en) | Cetp fragments | |
| NZ621439B2 (en) | Vaccine | |
| TW201420112A (zh) | 胜肽、醫藥化合物及該醫藥化合物之使用 |